Skip to Content

AC Immune SA ACIU Stock Quote

| Rating as of

NASDAQ:ACIU

Morningstar‘s Stock Analysis ACIU

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics ACIU

Company Profile ACIU

Business Description

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

Contact
EPFL Innovation Park, Building B
Lausanne, 1015, Switzerland
T +41 216939121
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 143